# Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children

> **NCT01495468** · PHASE3 · COMPLETED · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 343 (actual)

## Conditions studied

- Growth Hormone Deficiency

## Interventions

- **BIOLOGICAL:** PEG-somatropin

## Key facts

- **NCT ID:** NCT01495468
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-01
- **Final completion:** 2008-03
- **Target enrollment:** 343 (ACTUAL)
- **Last updated:** 2017-07-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01495468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01495468, "Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01495468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*